ArticleFrontiers in immunology2026
Procoagulant effects of extracellular vesicles in patients with livedo reticularis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Extracellular vesicles (EVs) are lipid-delimited particles that mediate intercellular communication and have been implicated in both autoimmune and prothrombotic conditions. Livedo reticularis (LR) is a cutaneous vascular pattern associated with impaired dermal arteriolar blood flow and increased vascular risk, yet the contribution of EVs to LR pathogenesis has not been studied. Objectives: To characterize the procoagulant properties, cellular origin, and proteomic profile of plasma-derived EVs in LR. Methods: Plasma-derived EVs were isolated from 12 LR patients and seven healthy controls. Tissue factor (TF) activity, EV concentration, proteomic cargo, and cellular origin were assessed using chromogenic assays, nanoparticle tracking analysis, mass spectrometry, and flow cytometry. Results: TF activity was significantly increased in LR plasma and was enriched within the small EV fraction. Sequential centrifugation demonstrated a stepwise reduction in TF activity, implicating both large and small EVs as contributors. EV concentrations did not differ between groups, indicating qualitative rather than quantitative differences. Proteomic analysis revealed a distinct EV cargo in LR, with widespread protein downregulation and enrichment of coagulation, vascular homeostasis, and VEGF signaling pathways. Notably, KLF8 was markedly reduced. The composition of cells of origin was different, as EVs from LR patients showed an increased leukocyte-derived and decreased platelet-derived profile. Conclusion: LR is associated with an EV-driven procoagulant and inflammatory phenotype characterized by TF activity, altered cargo, and immune-cell origin, suggesting a role for EV-mediated thrombo-inflammatory microvascular dysfunction in LR pathogenesis. Abundance of KLF8 is markedly reduced, which renders it a target for further mechanistic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.